Related Experiment Video

Updated: Jul 16, 2025

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

21.5K

Antimicrobial effect of platelet-rich fibrin: A systematic review of in vitro evidence-based studies

Vittorio Moraschini1,2, Richard J Miron3, Carlos Fernando de Almeida Barros Mourão4,5

  • 1Dental Research Division, Department of Periodontology, School of Dentistry, Veiga de Almeida University, Rio de Janeiro, Brazil.

Periodontology 2000
|September 23, 2023
PubMed

Insights

Platelet-rich fibrin (PRF) and its variations, including injectable PRF (I-PRF), horizontal PRF (H-PRF), and silver nanoparticle PRF (agNP-PRF), demonstrate significant antimicrobial potential against oral bacteria. These advanced PRF forms enhance antibacterial activity, offering promising applications in regenerative treatments.

Area of Science:

  • Biomaterials Science
  • Microbiology
  • Regenerative Medicine

Background:

  • Platelet-rich fibrin (PRF) is utilized in regenerative therapies.
  • Understanding the antimicrobial properties of PRF variations is crucial for optimizing clinical applications.
  • Existing literature lacks a comprehensive synthesis of PRF's antimicrobial potential across different formulations.

Purpose of the Study:

  • To systematically review and evaluate the in vitro antimicrobial potential of various platelet-rich fibrin (PRF) types.
  • To compare the antimicrobial efficacy of standard PRF against advanced forms like injectable PRF (I-PRF), PRF with silver nanoparticles (agNP-PRF), and horizontal PRF (H-PRF).
  • To assess the risk of bias in included studies and synthesize findings qualitatively.

Main Methods:

  • A systematic electronic search was conducted across four databases and gray literature up to January 2023.
  • Inclusion criteria focused on in vitro studies assessing the antimicrobial effects of different PRF types.
  • The modified OHAT tool was used for risk of bias assessment, and a qualitative critical analysis synthesized the results.

Main Results:

  • Sixteen studies published between 2013 and 2021 were included.
  • All PRF variations exhibited significant antimicrobial activity against 16 bacterial types from oral, periodontal, and endodontic environments, with antibacterial effects more pronounced than antifungal.
  • Injectable PRF (I-PRF), horizontal PRF (H-PRF), and silver nanoparticle PRF (agNP-PRF) demonstrated enhanced antimicrobial activity.
  • No included study was classified as having a high risk of bias.

Conclusions:

  • PRF variations possess significant antimicrobial activity, particularly against bacteria.
  • Advanced PRF formulations, including I-PRF, H-PRF, and agNP-PRF, show improved antimicrobial efficacy.
  • Further clinical studies are essential to validate the therapeutic effects of these enhanced platelet concentrates.
Keywords:
PRFantimicrobialsautologous platelet concentratesplatelet‐rich fibrin

More Related Videos

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

13.0K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

920

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.4K